New hope for kids with tough neuroblastoma: Three-Drug combo trial launches
NCT ID NCT02914405
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This early-phase study tests a new combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has come back or is hard to treat. The main goal is to see if the combination is safe and tolerable. About 44 children will take part across hospitals in the UK, Germany, and the USA.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University College London Hospital
London, London, NW1 2BU, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, SO16 6YD, United Kingdom
-
University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.